Agoracom Blog
«
»

INTERVIEW: Tetra Bio-Pharma Developing Pharma Derived From Cannabis and Other Medicinal Plants $TBP.ca

Posted by AGORACOM-JC at 11:41 AM on Tuesday, November 8th, 2016

Pharmaceutical Division – PhytoPain Pharma

  • Developing and commercialization of botanical based pharmaceuticals
  • Engaged in the development of medication to alleviate symptoms related to: Pain, Insomnia, anxiety disorder, in patients suffering from Cancer and other, chronic and terminal diseases

Recent Highlights

  • Signed a Supply Agreement with Access to Cannabis for Medical Purpose Regulations (“ACMPR”) licensed producer Aphria Inc.
  • For the supply of dried medical cannabis as an Active Pharmaceutical Ingredient (API) for PPP’s inhalation cannabis product PPP001
  • Acquired multiple intellectual property assets related to the initiation of manufacturing and distribution of products for natural health care including products containing extracts or oils derived from Cannabis sativa
  • Recently announced awarding of the NSERC Engage partnership grant with McGill University will allow AGTK to achieve its commercial strategy to launch Cannabis-derived supplements that comply with the existing regulations regarding cannabis and cannabinoid content

Hub On AGORACOM / Corporate Profile / Watch Interview

Tags: , , ,

This entry was posted on Tuesday, November 8th, 2016 at 11:41 am and is filed under AGORACOM Via Satellite, Medical Marijuana Stocks. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.